Active platelet-binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 7, 2010, Pages 1653-1656

  Peyvandi, F ^a   Hollestelle, M J ^b   Palla, R ^a   Merlini, P A ^c   Feys, H B ^d   Vanhoorelbeke, K ^c   Lenting, P J ^b   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PLATELET ADHESIVENESS; VON WILLEBRAND FACTOR;

EID: 77955046869     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03896.x     Document Type: Letter

References (16)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998, 67:395-424.
2. Schneider SW, Nuschele S, Wixforth A, Gorzelanny C, Alexander-Katz A, Netz RR, Schneider MF. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci USA 2007, 104:7899-903.
3. Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005, 56:173-91.
4. Hulstein JJ, de Groot PG, Silence K, Veyradier A, Fijnheer R, Lenting PJ. A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B. Blood 2005, 106:3035-42.
5. No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age. Circulation 2003, 107:1117-22.
6. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, Fressinaud E, van den Berg HM, de Groot PG, Lenting PJ. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 2007, 109:2430-7.
7. Feys HB, Liu F, Dong N, Pareyn I, Vauterin S, Vandeputte N, Noppe W, Ruan C, Deckmyn H, Vanhoorelbeke K. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006, 4:955-62.
8. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease. Focus on acute coronary syndromes. Circulation 2008, 117:1449-59.
9. Matsukawa M, Kaikita K, Soejima K, Fuchigami S, Nakamura Y, Honda T, Tsujita K, Nagayoshi Y, Kojima S, Shimomura H, Sugiyama S, Fujimoto K, Yoshimura M, Nakagaki T, Ogawa H. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol 2007, 100:758-63.
10. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006, 4:2490-3.
11. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost 2008, 6:583-8.
12. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007, 109:1998-2000.
13. Hollestelle MJ, Donkor C, Mantey EA, Chakravorty SJ, Craig A, Akoto AO, O'Donnell J, van Mourik JA, Bunn J. von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation. Br J Haematol 2006, 133:562-9.
14. Groot E, de Groot PG, Fijnheer R, Lenting PJ. The presence of active von Willebrand factor under various pathological conditions. Curr Opin Hematol 2007, 14:284-9.
15. Diener JL, Daniel Lagassé HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009, 7:1155-62.
16. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007, 116:2678-86.